Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma

Next Previous
Trial Profile

A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Cyclophosphamide; Vinorelbine
  • Indications Rhabdomyosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 16 Sep 2019 Results published in the Childrens Hospital Los Angeles Media Release.
  • 16 Sep 2019 According to an Childrens Hospital Los Angeles Media release, results from this study were recently published in the Journal of Clinical Oncology
  • 12 Sep 2019 Primary endpoint (Event Free Survival Probability- comparison between Bevacizumab and Temsirolimus containing regimens) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top